Antisense modulation of DYRK4 expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsKenneth W. Dobie, Susan M. Freier
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of DYRK4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding DYRK4. Methods of using these compounds for modulation of DYRK4 expression and for treatment of diseases associated with expression of DYRK4 are provided.
Claims20
A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding DYRK4, wherein said compound specifically hybridizes with said nucleic acid molecule encoding DYRK4 and inhibits the expression of DYRK4.
A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding DYRK4.
Dependencies are inferred from the claim text.